ESMO - Eur. Oncology· @myESMO · X·· 4 小时前评分45
正文 · 机器翻译
#ESMO26：在III期试验中，izalontamab brengitecan（#BispecificADC，靶向EGFR和#HER3）与ruzaltatug rezetecan（#ADC，靶向HER3）在局部晚期或#metastatic #EGFRmutant #NSCLC患者中显示出显著疗效
🔗 https://ow.ly/qpgc5100JU5
#InsightsbyESMO
136 浏览 · 0 赞 · 0 转发 · 0 回复
会议摘要
Phase II study of izalontamab brengitecan (Iza-bren) plus osimertinib in patients with EGFR mutant locally advanced or metastatic non-small cell lung cancer (NSCLC)
https://esmocongress.esmo.orgLBA50按 Proffered paper 1: Breast cancer, early and advanced stage 对上
PANKU-Breast01: Randomized phase III study of izalontamab brengitecan (iza-bren) in previously treated unresectable locally advanced or metastatic (LA/M) hormone receptor-positive/HER2-negative (HR+/HER2-) breast cancer (BC)
https://esmocongress.esmo.org来源：ESMO - Eur. Oncology · x.com